Korean Circ J.  2022 Apr;52(4):338-340. 10.4070/kcj.2021.0429.

Balancing Between Ischemic and Bleeding Risk in PCI Patients With ‘BiRisk’

• Park MW

• KMID: 2528028
• DOI: http://doi.org/10.4070/kcj.2021.0429

Abstract

No abstract available.

Reference

1. Kim HK, Ahn Y, Chang K, et al. 2020 Korean Society of Myocardial Infarction expert consensus document on pharmacotherapy for acute myocardial infarction. Korean Circ J. 2020; 50:845–866. PMID: 32969206.

2. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009; 30:1457–1466. PMID: 19351691.

3. Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017; 38:804–810. PMID: 28363222.

4. Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019; 393:2503–2510. PMID: 31056295.

5. Cao D, Mehran R, Dangas G, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol. 2020; 75:2711–2722. PMID: 32466887.

6. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021; 385:1643–1655. PMID: 34449185.

7. TCT. MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk 2021 [Internet]. New York (NY): TCT;2021. cited year month day. Available from: https://www.tctmd.com/slide/master-dapt-randomized-trial-abbreviated-antiplatelet-therapy-outcomes-high-bleeding-risk.

8. Escaned J, Cao D, Baber U, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021; 42:4624–4634. PMID: 34662382.

9. Lee YJ, Suh Y, Kim JS, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial. Korean Circ J. 2022; 52:324–337. PMID: 35129317.

10. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020; 323:2407–2416. PMID: 32543684.